What's the near term outlook for CTXR

The near-term outlook for Citius Pharmaceuticals (CTXR) appears to be cautious, with a bearish price trend forecasted over the next few days. Here's a detailed analysis:

1. **Current Price Trend**: The stock is currently between narrow resistance and wide resistance levels, indicating a bullish price trend. However, the forecast suggests a bearish trend over the next 12 days, with a sell advice.
2. **Support and Resistance Levels**: The current price is positioned between the narrow support level of $1.49 and the wide resistance level of $1.55. The stock is trading close to the narrow resistance level, which could pose a ceiling for the price in the near term.

3. **Forecast Price Trend**: The forecast for the next few days shows a bearish trend, with prices likely to decline towards the support level of $1.47. The forecast advises selling the stock, and the historical win rate for this type of forecast is 53.39%.

4. **Market Sentiment**: Despite the bearish forecast, recent news about the company, such as the distribution deal with Cencora, suggests potential upside momentum. However, the market may have already priced in these positive expectations, leading to a potential pullback in the near term.
5. **Technical Indicators**: The stock's closing price on July 21, 2025, was $1.44, which is below the narrow resistance level. The trading volume was 574,826 shares, indicating moderate activity.

|code|Ticker|Name|Date|Closing Price|Trading Volume|market_code|
|---|---|---|---|---|---|---|
|CTXR|CTXR.O|Citius|20250721|1.44|574826|186|

In conclusion, while there is potential for upside momentum due to the distribution deal, the near-term forecast suggests a bearish trend. Investors should exercise caution and consider the potential for price declines in the coming days.